Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen

Maturitas

Volumn 25, Issue 1, 1996, Pages 45-50

  Dijkhuizen, F P H L J ^a,b   Brolmann H A M ^a   Oddens, B J J ^a,c   Roumen, R M H ^a   Coebergh, J W W ^d   Heintz, A P M ^b  

^a ST JOSEPH HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c International Health Foundation Brussels   (Belgium)

^d The Netherlands   (Netherlands)

Author keywords

Breast cancer; Endometrial pathology; Postmenopause; Tamoxifen; Transvaginal ultrasonography

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFECT; ENDOMETRIUM; FEMALE; HUMAN; POSTMENOPAUSE; TRANSVAGINAL ECHOGRAPHY;

EID: 0030217941     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(96)01043-2     Document Type: Article

References (23)

1. [1] Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15, 71-85.
2. [2] Fornander T, Rutqvist LE, Cedermark B et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-120.
3. [3] Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660-664.
4. [4] Ugwumada AHN, Harding K. Uterine leiomyomata and endometrial proliferation in postmenopausal women treated with the anti-oestrogen tamoxifen. Eur J Obstet Gynecol Reprod Biol 1994; 54: 153-156.
5. [5] Nasri MN, Coast GJ. Correlation of ultrasound findings and endometrial histo-pathology in postmenopausal women. Br J Obstet Gynaecol 1989; 96: 1333-1338.
6. [6] Bakos O, Smith P, Heimer G. Transvaginal ultrasonography for identifying endometrial pathology in postmenopausal women. Maturitas 1995; 20: 181-189.
7. [7] Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990; 163: 119-123.
8. [8] Granberg S, Wikland M, Karlsson B, Norström A, Friberg L-G. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991; 164: 47-52.
9. [9] Nab HW, Kluck HM, Rutgers EJT, Coebergh JWW, Hop WCJ. Long-term prognosis of breast cancer: an analysis of 462 patients in a general hospital in south east Netherlands. Eur J Surg Oncol 1995; 21: 42-46.
10. [10] Brooks PG, Senden SP. Hysteroscopic findings after unsuccessful dilatation and curettage for abnormal bleeding. Am J Obstet Gynecol 1988; 158: 1354-1357.
11. [11] Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 1990; 35: 235-238.
12. [12] Van Leeuwen FE, Benraadt J, Coebergh JWW et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448-452.
13. [13] Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WH. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the NSABP B-14. J Natl Cancer Inst 1994; 86: 527-537.
14. [14] Cohen I, Rosen DJD, Shapira J et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994; 52: 185-190.
15. [15] Kedar RP, Bourne TH, Powles TJ et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343: 1318-1321.
16. [16] Goldstein SR. Postmenopausal endometrial fluid collection revisited: look at the doughnut rather than the hole. Obstet Gynecol 1994; 83: 738-740.
17. [17] Anteby E, Yagel S, Zacut D, Palti Z, Hochner-Celnikier D. False sonographic appearance of endometrial neoplasia in postmenopausal women treated with tamoxifen. Lancet 1992; 340: 433-434.
18. [18] Goldstein SR. Unusual ultrasonograhic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170: 447-451.
19. [19] Cohen I, Rosen DJD, Shapira J. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993; 100: 567-570.
20. [20] Bisset D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet 1994; 344: 1244.
21. [21] Amy J-J, Van Liedekerke D. Gynaecological monitoring during tamoxifen therapy. Lancet 1994; 345: 253-254.
22. [22] Cohen I, Altaras M, Shapira J, Tepper R, Beyth Y. Postmenopausal tamoxifen treatment and endometrial pathology. Obstet Gynecol Surv 1994; 49: 823-829.
23. [23] Neven P, De Muylder X, Van Belle Y, Campo R, Vanderick G. Tamoxifen and the uterus. Br Med J 1994; 309: 1313-1314.